食品药品管理局批准BridgeBio Pharma的新药丸Attruby 治疗一种罕见的心脏病 ATTR-CM The FDA approves BridgeBio Pharma's new pill, Attruby, to treat a rare heart condition, ATTR-CM.

林业发展局批准了BridgeBio Pharma的新药Attruby(atoramidis),以治疗成人的心血管病(ATTR-CM)。 The FDA has approved BridgeBio Pharma's new drug, Attruby (acoramidis), to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby(口服避孕药)稳定了TTR蛋白质,旨在减少心血管死亡和住院。 Attruby, an oral pill, stabilizes the TTR protein, aiming to reduce cardiovascular deaths and hospitalizations. 批准的依据是成功试用结果,显示存活率提高,住院人数减少。 The approval is based on successful trial results showing improved survival and reduced hospitalizations. BridgeBio与Orsini合作进行分销,与Bayer合作进行欧洲商业化。 BridgeBio has partnered with Orsini for distribution and Bayer for European commercialization. 该药物的价格和供应细节仍在最后确定中。 The drug's price and availability details are still being finalized.